Expression and prognostic significance of EpCAM

Journal of Cancer Molecules

Volumn 3, Issue 6, 2008, Pages 169-174

  Went, Philip ^a   Dimhofer, Stephan ^a   Schöpf, Daniel ^b   Moch, Holger ^c   Spizzo, Gilbert ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Carcinoid; EpCAM; Squamous cell carcinoma; Tissue microarray

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY;

ANTIGEN RETRIEVAL; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CARCINOID; CLONE; CORRELATION ANALYSIS; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; ENDOMETRIUM CARCINOMA; EPITHELIUM CELL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MICROWAVE RADIATION; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RELIABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STAINING; TISSUE MICROARRAY; TUMOR LOCALIZATION;

EID: 41949137882     PISSN: 18160735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ladwein M, Pape UF, Schmidt DS, Schnolzer M, Fledler S, Langbein L, Franke WW, Moldenhauer G, Zoller M. The cell-cell adhesion molecule EpCAM interacts directly with the tight junction protein claudin-7. Exp Cell Res 309: 345-357, 2005.
2. Class C, Wahl J, Orlicky DJ, Karaduman H, Schnolzer M, Kempf T, Zoller M. The tretraspanin D6.1A and its molecular partners on rat carcinoma cells. Biochem J 389: 99-110, 2005.
3. Schmidt DS, Klingbeil P, Schnolzer M, Zoller M. CD44 variant isoforms associate with tetraspanins and EpCAM. Exp Cell Res 297: 329-347, 2004.
4. Litvinov SV, Balzar M, Winter MJ, Bakker HA, Briaire-de Bruijn IH, Prins F, Fleuren GJ, Wamaar SO. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 139: 1337-1348, 1997.
5. Kuhn S, Koch M, Nubel T, Ladwein M, Antolovic D, Klingbeil P, Hildebrand D, Moldenhauer G. Langbein L, Franke WW, Weitz J, Zoller M. A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetrapanins promotes colorectal cancer progression. Mol Cancer Res 5: 553-567, 2007.
6. Baeuerie PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 96: 417-423, 2007.
7. Moldenhauer G, Momburg F, Moller P, Schwartz R Hammerling GJ. Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. Br J Cancer 56: 714-721, 1987.
8. Went PT, Lugli A, Meler S, Bundl M, Mirlacher M, Sauter G, Dimhofer S. Frequent EpCAM protein expression in human carcinomas. Hum Pathol 35: 122-126, 2004.
9. Went P, Vasel M, Bubendorf L, Terracciano L, Tomillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerie PA. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94: 128-135, 2006.
10. Stoecklein NH, Siegmund A, Scheunemann P, Luebke AM, Erbersdobler A, Verde PE, Elsenberger CF, Peiper M, Rohders A, Esch JS, Knoefel WT, Hosch SB. Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker. BMC Cacer 6: 165, 2006.
11. Herlyn M, Stopkowski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 76: 1438-1452, 1979.
12. Fields AF, Keller AM, Schwartzberg L, Bernard S, Pazdur R, Kardinal C, Cohen A, Schultz J, Eisenberg P, Berber L, Edmundson S, Wisse P. Edrecolomab (17-1A antibody) (EDR). In combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stop III colon cancer: results of a randomised north american phase III study. Proc Am Soc Clin Oncol 21: 508, 2002.
13. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funks I, Pichimeier H, Hirche H, Buggisch P, Witte J, Pichimayr R. Monoclonal antibody therapy for reseated Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 16: 1788-1794, 1996.
14. Quenneville J, Fitsialos D, Rasaomoelisolo M, Cross M, Glover N, MacDonald G. A phase I open-label study to evaluate safety, tolerability and pharmacokinetic (PK) profile of VB4 345, an anti-EpCAM immunotoxin, in subjects with SCCHN. J Clin Oncol 23: A5536, 2005.
15. Gires O, Pocki S, Chapman RD, Munz M. Targeted gene expression using a 1.1 kilobase promoter fragment of the tumour-associated antigen EpCAM. Anticancer Res 24: 3715-3721, 2004.
16. Osta WA, Chen Y, Mikhitarian K, Mias M, Salem M, Hannun YA, Cole DJ, Gillanders WE. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64: 5818-5824, 2004.
17. Bubendorf L, Nocitto A, Moch H, Souter G. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 195: 72-79, 2001.
18. Went P, Dimholer S, Salvisberg T, Amin W, Lim BID, Diener PA, Moch H. Expression of epithelial cell adhesion molecule (Ep-Cam) in renal epithelial tumors. Am J Surg Pathol 29: 83-88, 2005.
19. Lammers R, Gissert C, Grunebach F, Marxer A, Vogel W, Buhring HJ. Monoclonal antibody 9C4 recognizes epithelial cellular adhesion molecule, a cell surface antigen expressed in early steps of erythropoiesis. Exp Hematol 30: 537-545, 2002.
20. Spizzo G, Went P, Dimhofer S, Obrist P, Simon R, Spichtin H, Maurer R, Metzger U, von Castelberg B, Bart R, Stopaschinskaya S, Kochill OR, Hass P, Mross F, Zuber M, Dietrich H, Bischoff S, Mirlacher M, Sauter G, Gasit G. High Ep-CAM expression is associated with poor prognosis in nods-positive breast cancer. Breast Cancer Res Treat 86: 207-213, 2004.
21. Spizzo G, Obrist P, Ensinger C, Theuri I, Dunser M, Ramoni A, Gunsillus E, Elbi G, Mikuz G, Gasti G. Prognostic significance of Ep-CAM and Her-2/ neu overexpression in invasive breast cancer. Int J Cancer 98: 883-888, 2002.
22. Spizzo G, Gasti G, Wolf D, Gunsillus I, Stourer M, Fong D, Amberger A, Margrelter R, Obrist P. Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 88: 574-578, 2003.
23. Gasti G, Spizzo G, Obrist P, Dunsec M, Mikuz G. Ep-CAM overexpression in broest cancer as a predictor of survival. Lancet 358: 1981-1982, 2000.
24. Spizzo G, Went P, Dimholer S, Obrist P, Moch H, Baeuerie PA, Mueller-Holzner E, Marth C, Gasti G, Zelmet AG. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 103: 483-488, 2006.
25. Sellgson DO, Pentuck AJ, Liu X, Huang Y, Horvath S, Bul MH, Han KR, Correa AJ, Eava M, Tze S, Belldegrun AS, Figlin RA. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res 10: 2659-2669, 2004.
26. Zellweger T, Ninck C, Bloch M, Mirlacher M, Kolvisto PA, Holin H, Mihatsch M, Gasser T, Bubendorl L. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 113: 619-628, 2005.
27. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 4: 295-302, 1998.
28. Poczalek RB, Myers RB, Manne U, Oelschlager DK, Weiss, HL, Bostwick DG, Grizzle WE. Ep-CAM levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 162: 1462-1466, 1999.
29. Plyathilske CJ, Frost AR, Weiss H, Manne U, Heimburger DC, Grizzle WE. The expression of Ep-CAM (17-1A) in aquamous cell cancer of the lung. Hum Pathol 31: 482-487, 2000.
30. Moch H, Oberholzer M, Christen H, Buser M, Dalquen P, Wegmann W, Gudat F. Diagnostic tools for differentiating pleural mesothelioma from lung adenocarcinoma in paraffin embedded tissue. II. Design of an expert system and its application to the diagnosis of mesothelioma. Virchows Arch A Pathol Anat Histopathol 423: 493-496, 1993.
31. Rultenbeek T, Gouw AS, Poppema S. Immunocytology of body cavity flulds. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells. Arch Pathol Lab Med 118: 265-269, 1994.
32. Moch H, Oberholzer M, Dalquen P, Wegmann W, Gudet F. Diagnostic tools for differentiating between pleural mesothelioma and lung adanocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings. Virchows Arch A Pathol Anat Histopathol 423: 19-27, 1993.
33. Kimura H, Kato H, Farled A, Sohda M, Nakajima, M, Fukal Y, Miyazaki T, Masuda N, Fukuchi M, Kuwano H. Prognostic significance of EpCAM expression in human esophageal cancer. Int J Oncol 30: 171-179, 2007.